Royalty Pharma plc (RPRX) on Thursday reported higher first-quarter earnings, supported mainly by growth in income from financial royalty assets.
Net income before tax increased to $468 million from $434 million previously.
Operating income rose to $563 million from $534 million in the prior-year quarter.
Net income attributable to Royalty Pharma climbed to $295 million from $239 million a year earlier.
Total income and other revenues grew to $631 million from $568 million last year.
Income from financial royalty assets increased to $595 million from $539 million, while other royalty income and revenues rose to $36 million from $29 million.
The company said Royalty Receipts grew 13% to $887 million in the first quarter, driven by Tremfya, Voranigo and Evrysdi.
Portfolio Receipts increased by 10% to $925 million.
For the full year, Royalty Pharma now expects Portfolio Receipts to be between $3.325 billion and $3.450 billion, up from the prior outlook of $3.275 billion - $3.425 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.